Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 6, 2014, Pages 2447-2451

  Wu, Xiang Mei ^a,b   Liu, Xing ^c   Jiao, Qing Fang ^a,d   Fu, Shao Yue ^a,d   Bu, You Quan ^a,d   Song, Fang Zhou ^a,d   Yi, Fa Ping ^a,d  

^a Chongqing Molecular Medicine and Cancer Research Center   (China)

^b Department of Physioloy ^*  (China)

^c Chongqing Children's Hospital   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

CaSki cell; Cervical cancer; E6 E7 protein; Human papillomavirus

Indexed keywords

E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HLA ANTIGEN CLASS 1; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN; WART VIRUS VACCINE;

ADENOVIRIDAE; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; C57BL MOUSE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; MOUSE; PAPILLOMAVIRUS INFECTIONS; TUMOR CELL CULTURE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRESSOR PROTEINS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84899790980     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.6.2447     Document Type: Article

References (25)

1. Banchereau J, Briere F, Caux C, et al. (2000). Immunobiology of dendritic cells. Annu Rev Immunol, 18, 767-811.
2. Barrios K, Celis E (2012). TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother, 61, 1307-17.
3. Chen Z, Kamath P, Zhang S, et al. (1996). Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Cancer Gene Ther, 3, 18-23.
4. Evan G, Littlewood T. (1998). A matter of life and cell death. Science, 281, 1317-22.
5. Frazer IH, Quinn M, Nicklin JL, et al. (2004). Phase I study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine, 23, 172-181.
6. Koutsky LA, Harper DM. (2006). Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine, 24, 114-21.
7. Levine AJ. (1997). P53, the cellular gatekeeper for growth and division. Cell, 88, 323-31.
8. Liu Z, Xu X, Hsu HC, et al. (2003). CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CIIinduced arthritis. J Clin Invest, 112, 1332-41.
9. Lu L, Lee WC, Takayama T, et al. (1999). Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-β, and CTLA4Ig). J Leukocyte Biol, 66, 293-6.
10. Matsue H, Matsue K, Walters M, et al. (1999). Induction of antigen-specific immunosuppression by CD95L cDNAtransfected 'killer' dendritic cells. Nat Med, 5, 930-7.
11. Milde-Langosch K, Riethdorf S, Loning T. (2000). Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications. Virchows Arch, 437, 227-33.
12. Morelli AE, Thomson AW. (2003). Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev, 196, 125-46.
13. Morita Y, Yang J, Gupta R, et al. (2001). Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest, 107, 1275-84.
14. Munger K, Basile J, Duensing S, et al. (2001). Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene, 20, 7888-98.
15. Parkin DM, Bray F. (2006). The burden of HPV-related cancers. Vaccine, 24, 11-25.
16. Steinman RM, Nussenzweig MC. (2002). Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA, 99, 351-8.
17. Sufang Wu, Li Meng, Shixuan Wang, et al. (2006). Reversal of the malignant phenotype of cervical cancer CaSki Cells through adeno-associated virus-mediated delivery of HPV16 E7 antisense RNA. Clin Cancer Res, 12, 2032-7.
18. Walboomers JM, Jacobs MV, Manos MM, et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.
19. Watanabe S, Kagamu H, Yoshizawa H, et al. (2003). The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol, 171, 5828-36.
20. Werness BA, Levine AJ, Howley PM. (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 248, 76-9.
21. Wheeler CM. (2007). Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol, 4, 224-35.
22. Young A. (2010). HPV vaccine acceptance among women in the Asian Pacific: a systematic review of the literature. Asian Pac J Cancer Prev, 11, 641-9.
23. Zeng Q, Peng S, Monie A, et al. (2011). Control of ervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther, 22, 809-19.
24. Zur Hausen H. (1996). Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta, 1228, F55-78.
25. zur Hausen H. (2000). Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst, 92, 690-8.